Compare Amylx Pharmaceuticals Inc (AMLX) vs Gitlab Inc (GTLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Gitlab Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Gitlab Inc trades at $32.87 (market cap $5.48B). The key difference: Gitlab Inc is far larger — about 2.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | GTLB | |
|---|---|---|
Market Cap | $1.98B | $5.48B |
Sector | Health | Technology |
52-Week High | $18.70 | $51.04 |
52-Week Low | $7.64 | $19.42 |
Enterprise Value | $1.70B | $4.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
GitLab (GTLB) trades at $32.42, down 4.25% today, but maintains a bullish technical outlook with strong moving average signals. The company shows impressive revenue growth, reaching $759 million in 2025, with consistent earnings beats in recent quarters. Analyst sentiment is mixed with 36.7% buy ratings, while the stock trades near consensus price target of $31.93. Recent news highlights GitLab's leadership in DevSecOps and strategic AI partnerships.
GitLab presents a growth story with strong market positioning but faces profitability challenges. The stock offers upside potential from AI-driven software demand and enterprise adoption, though high valuation multiples and negative cash flow pose risks. Investors should weigh the company's strategic position against its path to sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
